120 related articles for article (PubMed ID: 15681898)
1. Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C.
Uchida M; Hamada A; Yamasaki M; Fujiyama S; Sasaki Y; Saito H
Drug Metab Pharmacokinet; 2004 Dec; 19(6):438-43. PubMed ID: 15681898
[TBL] [Abstract][Full Text] [Related]
2. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.
Khakoo S; Glue P; Grellier L; Wells B; Bell A; Dash C; Murray-Lyon I; Lypnyj D; Flannery B; Walters K; Dusheiko GM
Br J Clin Pharmacol; 1998 Dec; 46(6):563-70. PubMed ID: 9862245
[TBL] [Abstract][Full Text] [Related]
3. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
Maddrey WC
Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection.
Tsubota A; Hirose Y; Izumi N; Kumada H
Br J Clin Pharmacol; 2003 Apr; 55(4):360-7. PubMed ID: 12680884
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
[TBL] [Abstract][Full Text] [Related]
6. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
González-Peralta RP; Kelly DA; Haber B; Molleston J; Murray KF; Jonas MM; Shelton M; Mieli-Vergani G; Lurie Y; Martin S; Lang T; Baczkowski A; Geffner M; Gupta S; Laughlin M;
Hepatology; 2005 Nov; 42(5):1010-8. PubMed ID: 16250032
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
Scott LJ; Perry CM
Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
[TBL] [Abstract][Full Text] [Related]
8. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
Hashimoto Y; Kanto H; Itoh M
J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
[TBL] [Abstract][Full Text] [Related]
9. Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy.
Nomura H; Miyagi Y; Tanimoto H; Yamashita N; Ito K; Masaki N; Mizokami M
J Gastroenterol Hepatol; 2012 Sep; 27(9):1461-6. PubMed ID: 22554247
[TBL] [Abstract][Full Text] [Related]
10. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load.
Tsubota A; Akuta N; Suzuki F; Suzuki Y; Someya T; Kobayashi M; Arase Y; Saitoh S; Ikeda K; Kumada H
Intervirology; 2002; 45(1):33-42. PubMed ID: 11937769
[TBL] [Abstract][Full Text] [Related]
11. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
Poynard T; Marcellin P; Bissery A; Myers RP; Moussalli J; Degos F; Dhumeaux D; Riachi G; Bronowicki JP; Brissot P; Buffet C; Serfaty L; Naveau S; Sogni P; Beaugrand M; Gayno S; Larrey D; Samuel D; Eugene C; Pol S; Bedossa P; Daurat V; Chaumet-Riffaud P;
J Viral Hepat; 2003 May; 10(3):197-204. PubMed ID: 12753338
[TBL] [Abstract][Full Text] [Related]
12. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.
Sulkowski MS; Wasserman R; Brooks L; Ball L; Gish R
J Viral Hepat; 2004 May; 11(3):243-50. PubMed ID: 15117326
[TBL] [Abstract][Full Text] [Related]
13. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
de Lédinghen V; Trimoulet P; Winnock M; Foucher J; Bourlière M; Desmorat H; Canva V; Capron D; Lévy S; Mion F; Mannant PR; Chêne G; Fleury H; Couzigou P; Bernard PH;
J Hepatol; 2002 May; 36(5):672-80. PubMed ID: 11983451
[TBL] [Abstract][Full Text] [Related]
14. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.
Sjogren MH; Sjogren R; Holtzmuller K; Winston B; Butterfield B; Drake S; Watts A; Howard R; Smith M
Dig Dis Sci; 2005 Apr; 50(4):727-32. PubMed ID: 15844709
[TBL] [Abstract][Full Text] [Related]
15. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.
Wirth S; Ribes-Koninckx C; Calzado MA; Bortolotti F; Zancan L; Jara P; Shelton M; Kerkar N; Galoppo M; Pedreira A; Rodriguez-Baez N; Ciocca M; Lachaux A; Lacaille F; Lang T; Kullmer U; Huber WD; Gonzalez T; Pollack H; Alonso E; Broue P; Ramakrishna J; Neigut D; Valle-Segarra AD; Hunter B; Goodman Z; Xu CR; Zheng H; Noviello S; Sniukiene V; Brass C; Albrecht JK
J Hepatol; 2010 Apr; 52(4):501-7. PubMed ID: 20189674
[TBL] [Abstract][Full Text] [Related]
16. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.
Enríquez J; Gallego A; Torras X; Pérez-Olmeda T; Diago M; Soriano V; Luján MS; García-Samaniego J
J Viral Hepat; 2000 Nov; 7(6):403-8. PubMed ID: 11115050
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon-alpha(2b) and ribavirin.
Ahn J; Flamm S
Expert Rev Anti Infect Ther; 2004 Feb; 2(1):17-25. PubMed ID: 15482168
[TBL] [Abstract][Full Text] [Related]
19. Adverse cutaneous reactions to interferon alfa-2b plus ribavirin therapy in patients with chronic hepatitis C virus.
Manjón-Haces JA; Vázquez-López F; Gómez-Díez S; Hidalgo-García A; Pérez-Alvarez R; Soler-Sánchez T; Pérez-Oliva N
Acta Derm Venereol; 2001; 81(3):223. PubMed ID: 11558891
[No Abstract] [Full Text] [Related]
20. First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C.
Reiser M; Buggisch P; Grossmann J; Koop K; Wursthorn K; Schmiegel W
Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1299-304. PubMed ID: 14624153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
